sofosbuvir has been researched along with s 8932 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 9 (90.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balzarini, J; Mehellou, Y; Rattan, HS | 1 |
| Boccuto, A; Crespan, E; De Angelis, M; Decroly, E; Dragoni, F; Eydoux, C; Giavarini, G; Maga, G; Marchi, S; Martina, MG; Montomoli, E; Nencioni, L; Radi, M; Trombetta, CM; Vicenti, I; Zazzi, M | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Elfiky, AA | 1 |
| Perišić, O | 1 |
| Chien, M; Jockusch, S; Ju, J; Kalachikov, S; Kumar, S; Li, X; Morozova, I; Russo, JJ; Tao, C | 1 |
| Chen, S; Song, W; Yi, Z; Yuan, Z; Zhang, Y | 1 |
| Azzam, EB; Elfiky, AA; Shafaa, MW | 1 |
| Chao, CM; Hsueh, PR; Lai, CC | 1 |
| Biering, SB; Chien, M; Dugast-Darzacq, C; Garzia, A; Graham, TGW; Jockusch, S; Ju, J; Meyer, C; Näär, AM; Nguyenla, X; Patel, DJ; Russo, JJ; Schaletzky, J; Stanley, S; Stroumza, J; Tao, C; Tuschl, T; Van Dis, E; Wang, X; Wehri, E; Xie, W; Yamashiro, LH; Zhu, C | 1 |
2 review(s) available for sofosbuvir and s 8932
| Article | Year |
|---|---|
The ProTide Prodrug Technology: From the Concept to the Clinic.
Topics: Animals; Chemistry, Pharmaceutical; Humans; Nucleosides; Prodrugs; Structure-Activity Relationship | 2018 |
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Carbamates; Cobicistat; COVID-19 Drug Treatment; Darunavir; Dibenzothiepins; Drug Combinations; Drug Therapy, Combination; Humans; Imidazoles; Indoles; Iran; Lopinavir; Morpholines; Pyrazines; Pyridones; Pyrrolidines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Triazines; Valine | 2021 |
8 other study(ies) available for sofosbuvir and s 8932
| Article | Year |
|---|---|
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
Topics: Antiviral Agents; Flavivirus; Molecular Targeted Therapy; Orthomyxoviridae; Purines; SARS-CoV-2; Virus Replication | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Alphacoronavirus; Amino Acid Sequence; Antiviral Agents; Betacoronavirus; Catalytic Domain; Computational Biology; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Guanosine Monophosphate; Guanosine Triphosphate; Humans; Molecular Docking Simulation; Pneumonia, Viral; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Ribavirin; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sequence Alignment; Sequence Homology, Amino Acid; Sofosbuvir; Thermodynamics; Uridine Triphosphate; Viral Proteins | 2020 |
Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Viral; Antigen-Antibody Reactions; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Eflornithine; Humans; Hydrophobic and Hydrophilic Interactions; Ivermectin; L-Lactate Dehydrogenase; Models, Molecular; Molecular Docking Simulation; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Proline; Protein Binding; Protein Conformation; Protein Interaction Mapping; Receptors, Glycine; Saposins; SARS-CoV-2; Sofosbuvir; Spike Glycoprotein, Coronavirus; Structure-Activity Relationship | 2020 |
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; Drug Discovery; Drug Repositioning; Exonucleases; Hepacivirus; Hepatitis C; Humans; Pandemics; Pneumonia, Viral; Prodrugs; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication | 2020 |
A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Chromosomes, Artificial, Bacterial; COVID-19; COVID-19 Drug Treatment; HEK293 Cells; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Replicon; RNA-Binding Proteins; SARS-CoV-2; Sofosbuvir; Vero Cells; Virus Replication | 2021 |
The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Humans; Molecular Docking Simulation; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Sofosbuvir | 2022 |
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Hepacivirus; Hepatitis C; Humans; Lung; Nucleosides; SARS-CoV-2; Sofosbuvir | 2022 |